Market Data Current As Of: September 12, 2026
Related Competitor Intelligence
Compare market positioning with top industry peers
Explore Bayer
Core profile pages, annual revenue records, and related research hubs for this company.
Compare market positioning with top industry peers
Explore Bayer
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$49.5B
Market Cap
$31.8B
Employees
99,700
Bayer is navigating one of the most turbulent, crisis-ridden periods in its storied corporate history. Under CEO Bill Anderson, the German conglomerate generated exactly $51.2 billion in revenue but trades at a severely depressed $31.8 billion market cap with a workforce of exactly 99700 employees. The financial narrative in 2026 is overshadowed by the catastrophic $63 billion acquisition of Monsanto; Bayer remains trapped in endless, multi-billion-dollar litigation regarding Roundup weedkiller. To survive the immense financial strain and appease furious activist investors, Anderson has implemented a radical decentralized management structure ('Dynamic Shared Ownership') and slashed thousands of management roles, while resisting intense pressure to break up the company by spinning off the Consumer Health division to rescue the struggling Pharmaceuticals pipeline.
Revenue Trend Analysis
YoY Change
-2.6%
3-Year CAGR
-0.8%
Peak Year
2023
Trend
Declining Trend
Bayer AG has reported revenue across 4 fiscal years, compounding at -0.8% annually over 3 years. The most recent year saw a 2.6% decline versus the prior year. Revenue peaked in 2023 at $51.9B. Out of 3 reported periods, 1 showed growth and 2 showed a decline.
| Fiscal Year | Revenue | YoY Change |
|---|---|---|
| FY2025 | $49.5B | -2.6% |
| FY2024 | $50.8B | -2.1% |
| FY2023 | $51.9B | +2.4% |
| FY2022 | $50.7B | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Bayer AG reported approximately $51.2B in fiscal year 2025 with a team of 99,700 employees worldwide.
Bayer AG strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.
Financial performance in Pharmaceuticals / Life Sciences / Agriculture is driven by steady cash generation and pricing power, enabling Bayer AG to reinvest in high-return strategic initiatives.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Bayer AG Revenue & Financials." CorpDigest, https://corpdigest.com/company/bayer/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Bayer AG reported $50B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/bayer/financials" target="_blank" rel="noopener">CorpDigest — Bayer AG financials</a></div>